- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05373784
FMT in Uncomplicated Diverticulitis
Outcomes of Fecal Microbiota Transplantation (FMT) in Uncomplicated Diverticulitis: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to assess the safety and efficacy of fecal microbiota transplantation (FMT) in treating uncomplicated diverticulitis. FMT will be delivered via colonoscopy using donor stool. Fecal material samples obtained from the University of Minnesota Microbiota Therapeutics Program (UMMTP) will be used each patients FMT. These samples undergo FDA mandated testing prior to being used as donor samples.
Recipients will undergo FMT via Colonoscopy at UMASS Memorial Medical Center and will be monitored for one hour after the procedure to ensure they are not experiencing any adverse events. They will receive a phone call 24 hours and 2 weeks after their procedure to ensure that they are at their baseline health. Recipients follow-up visits will occur at one month, 3 month, 6 months and 1 year post FMT.
Baseline stool samples will be collected from both the recipients and the UMMTP samples for baseline metagenomic sequencing. Recipient stool samples will be obtained weekly for the first month, then at 3 months, 6 months and 1 year. Microbiome analyses will also performed on recipient all stool samples post FMT to assess for successful engraftment of donor's microbiota onto the recipient's.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Justin A Maykel, MD
- Phone Number: 508-334-8195
- Email: justin.maykel@umassmemorial.org
Study Contact Backup
- Name: Alexandra M Onyiego, MD
- Phone Number: 508-334-8195
- Email: alexandra.onyiego@umassmemorial.org
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Recruiting
- UMASS Memorial Medical Center
-
Contact:
- Justin A Maykel, MD
- Phone Number: 508-334-8195
- Email: justin.maykel@umassmemorial.org
-
Contact:
- Alexandra M Onyiego, MD
- Phone Number: 508-334-8195
- Email: alexandra.onyiego@umassmemorial.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Recipient Inclusion Criteria:
- Age >18
- One or more prior episode(s) of uncomplicated diverticulitis, as confirmed by imaging and clinical symptoms.
- Eligible for surgical resection
Recipient Exclusion Criteria:
- Subjects <18 years of age
- Patients with active diverticulitis flare
- Evidence of complicated diverticulitis (diverticulitis with abscess/phlegmon, bleeding, stricture, fistula or perforation) on imaging
- Prior fecal transplant
- Patients unable to provide informed consent
- Pregnant and/or breastfeeding women
- Prisoners
- Students
- Prior small or large bowel obstruction within the past year
- Prior major gastrointestinal or intra-abdominal surgery
- Any major illness or condition that may substantially increase risks to the recipient based on the investigator's judgment.
- Sexually active women who adhere to natural family planning alone
Donor Inclusion Criteria:
- Adult patients ≥18 years old
- Colonoscopy screening as recommended by the American Cancer Society. However, it is to be noted that only recipients will undergo colonoscopy for receipt of FMT as part of the study, not donors. We will only ensure that the prospective donor follows the recommended guidelines for screening colonoscopy, which are to begin at the age of 45. If the donor does not meet such guidelines, s/he will not be allowed to proceed as a donor. If a donor is not yet eligible to undergo screening colonoscopy (i.e., younger than 45), this will not be required of him/her."
- Able to provide informed consent
Donor Exclusion Criteria:
- History of diverticulitis
- Recent COVID-19 infection, confirmed or suspected exposure to COVD-19 within the past eight weeks. Such subjects will be excluded irrespective of negative COVID nasopharyngeal test.
Risk of infectious agent
- Known exposure to HIV, syphilis, or viral hepatitis (within the previous 12 months)
- High-risk sexual behaviors including sexual contact with anyone with HIV/AIDS or hepatitis, men who have sex with men, sex for drugs or money
- Use of illicit intravenous (IV) drug use
- Tattoo or body piercing within 6 months
- Incarceration within previous 12 months
- Known current communicable disease (e.g., COVID 19, Influenza, STDs, HIV/AIDS, Hepatitis B and C)
- Risk factors for variant Creutzfeldt-Jacob disease to prevent potential transmission of abnormal/pathologic prions (cellular proteins), which are the basis of this disease.
- Receipt of blood transfusion from country other than the United States of America (USA) and Canada in the previous 6 months
Individuals who are at a higher risk for colonization with multi-drug resistant organisms (MDRO):
- Health care workers
- Persons who have been hospitalized or discharged from long-term care facilities in the past 30 days
- Persons who regularly attend outpatient medical or surgical clinics
- Persons who have engaged in medical tourism in the past 30 days
Gastrointestinal comorbidities
- History of inflammatory bowel disease
- History of celiac disease
- History of irritable bowel syndrome, idiopathic chronic constipation, or chronic diarrhea
- History of gastrointestinal malignancy
Other
- Antibiotic use within the preceding 90 days
- Ingestion of a potential allergen (e.g., nuts) where recipient has a known allergy to this agent within the past 30 days
- Systemic autoimmunity (e.g., multiple sclerosis, connective tissue disease)
- Chronic pain syndromes (e.g., chronic fatigue syndrome, fibromyalgia)
- Fever, defined as temperature of 100 F or 38.7C, on the day of stool donation. Potential donors will be allowed to re-screen within 1 week if febrile on the day of stool donation. .
- Sexually active women who adhere to natural family planning alone as method of contraception
- Prisoners
- Students
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMT cohort
This will be a single-arm pilot study of patients with uncomplicated diverticulitis.
All subjects enrolled as recipients will undergo FMT via colonoscopy.
|
Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual.
This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management.
FMT can be delivered via capsule endoscopy or via colonoscopy.
In this study, it will be administered via colonoscopy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of diverticular flares/attacks since FMT
Time Frame: 1 year
|
After FMT, recipients/participants will be asked to report the number of diverticulitis episodes they have experienced since FMT
|
1 year
|
Number of emergency room visits and hospitalizations due to diverticulitis since FMT
Time Frame: 1 year
|
After FMT, recipients/participants will be asked to report the number of times (if any) they presented to the emergency room or were hospitalized due to diverticulitis.
|
1 year
|
Number of courses of antibiotics required for the treatment of diverticulitis since FMT
Time Frame: 1 year
|
After FMT, recipients/participants will be asked to report whether they required any antibiotics due to diverticulitis
|
1 year
|
Necessity for surgery
Time Frame: 1 year
|
After FMT, recipients/participants will be asked to report whether they required surgery to treat diverticulitis
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Justin A Maykel, MD, UMass Chan Medical School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000055
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diverticulitis
-
Hospital Central de la Defensa Gómez UllaCompletedDiverticulitis | Diverticulitis Colon | Diverticulitis of Sigmoid | Diverticulitis; Perforation, BowelSpain
-
Sebastiano BiondoRecruiting
-
University of AarhusOdense University Hospital; Aarhus University Hospital; University of Southern... and other collaboratorsRecruiting
-
Ente Ospedaliero Ospedali GallieraCompletedPeritonitis Caused by Perforated Left-sided Colon DiverticulitisItaly
-
Tepecik Training and Research HospitalCompleted
-
Sealantis Ltd.WithdrawnColorectal Cancer | Diverticulitis Colon
-
Uppsala UniversityCompletedColonic DiverticulitisSweden
-
Uppsala UniversityLandstinget i VärmlandCompleted
-
Hospital General Universitario Reina Sofía de MurciaCompletedDiet Modification | Diverticulitis | Dietary Modification | Diverticulitis, Colonic | Acute Diverticulitis | Uncomplicated Diverticular Disease | Diverticulitis of SigmoidSpain
-
Uppsala UniversitySahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Danderyd... and other collaboratorsRecruiting
Clinical Trials on Fecal Microbiota Transplantation (FMT)
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAllogeneic Hematopoietic Stem CellUnited States
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
Massachusetts General HospitalCompleted
-
The Second Hospital of Nanjing Medical UniversityFuzhou General HospitalUnknown
-
University Hospital of North NorwayOslo University Hospital; Haukeland University Hospital; Sorlandet Hospital HF; Alesund HospitalActive, not recruitingIrritable Bowel SyndromeNorway
-
Susy HotaSinai Health System, Ontario, Canada; University of Toronto, Ontario, Canada; The Toronto Invasive Bacterial Diseases Network, Ontario, Canada and other collaboratorsSuspended
-
Brigham and Women's HospitalIcahn School of Medicine at Mount Sinai; The Miriam Hospital; Indiana UniversityCompletedInflammatory Bowel Diseases | Clostridium Difficile InfectionUnited States
-
Children's Hospital Los AngelesCompleted
-
Wiebke Kristin FenskeMedical University of GrazRecruitingDiabetes | Metabolic Syndrome | Insulin Resistance | PreDiabetes | Morbid ObesityAustria
-
Memorial Sloan Kettering Cancer CenterCompletedCancer | C. Difficile InfectionUnited States